Open Access
CC BY-NC-ND 4.0 · Endosc Int Open 2024; 12(01): E108-E115
DOI: 10.1055/a-2220-2740
Original article

EUS-guided hepaticogastrostomy versus percutaneous transhepatic biliary drainage after failed ERCP: A propensity score-matched analysis

Authors

  • Nicholas J Koutlas

    1   Gastroenterology, Wake Forest School of Medicine, Winston-Salem, United States (Ringgold ID: RIN12279)
  • Swati Pawa

    1   Gastroenterology, Wake Forest School of Medicine, Winston-Salem, United States (Ringgold ID: RIN12279)
  • Greg Russell

    2   Biostatistics, Wake Forest School of Medicine, Winston-Salem, United States (Ringgold ID: RIN12279)
  • Taylor Ferris

    3   Department of Medicine, Wake Forest School of Medicine, Winston-Salem, United States (Ringgold ID: RIN12279)
  • Janardhana Ponnatapura

    4   Interventional Radiology, Wake Forest School of Medicine, Winston-Salem, United States (Ringgold ID: RIN12279)
  • Rishi Pawa

    1   Gastroenterology, Wake Forest School of Medicine, Winston-Salem, United States (Ringgold ID: RIN12279)
Preview

Abstract

Background and study aims Percutaneous transhepatic biliary drainage (PTBD) is the traditional second-line option after unsuccessful endoscopic retrograde cholangiopancreatography (ERCP). Endoscopic ultrasound-guided hepaticogastrostomy (EUS-HG) is a viable alternative to PTBD. Our study aimed to compare outcomes of EUS-HG and PTBD for benign and malignant biliary diseases following failed ERCP.

Patients and methods This single-center study retrospectively analyzed patients undergoing EUS-HG and PTBD for benign and malignant biliary disorders. A propensity score-matched analysis was performed using age, sex, and Charlson Comorbidity Index. The primary outcome was clinical success, which we defined as a decrease in total bilirubin by ≥ 50% at 2 weeks for malignant disease and resolution of the biliary disorder for benign disease.

Results In total, 41 patients underwent EUS-HG and 138 patients underwent PTBD. After propensity score matching in a 1:2 ratio, 32 EUS-HG patients were matched with 64 PTBD. Technical success was achieved in 29 of 32 (91%) for EUS-HG and 63 of 64 (98%) for PTBD (P=0.11). Clinical success was 100% for EUS-HG and 75% for PTBD (P=0.0021). EUS-HG was associated with a lower adverse event rate (EUS-HG 13% vs. PTBD 58%, P <0.0001), shorter procedure duration (median 60 vs. 115 minutes, P <0.0001), shorter post-procedure length of stay (median 2 vs. 4 days, P <0.0001), and fewer reinterventions (median 1 vs. 3, P <0.0001).

Conclusions Our results suggest that EUS-HG is superior to PTBD in the treatment of benign and malignant biliary disorders after failed ERCP.



Publikationsverlauf

Eingereicht: 19. Juli 2023

Angenommen nach Revision: 16. November 2023

Artikel online veröffentlicht:
19. Januar 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany